A randomized, double-blind, placebo-controlled study assessing the anti-inflammatory effects of ketamine in cardiac surgical patients

J Cardiothorac Vasc Anesth. 2006 Apr;20(2):217-22. doi: 10.1053/j.jvca.2005.12.005. Epub 2006 Mar 9.

Abstract

Objective: To determine whether ketamine administration affects markers of inflammation in cardiac surgery with cardiopulmonary bypass (CPB) and to investigate differences between 2 low-dose ketamine regimens.

Design: Prospective, randomized, placebo-controlled trial.

Setting: Single-center university hospital.

Participants: Patients undergoing cardiac surgery with CPB.

Intervention: Patients (n = 50) were randomized to 1 of 3 groups: ketamine, 0.25 mg/kg (n = 15); ketamine, 0.5 mg/kg (n = 18);or placebo (n = 17) in a double-blind manner at the time of induction of general anesthesia.

Measurements and main results: Serum C-reactive protein (CRP) and interleukin (IL)-6, IL-8, and IL-10 were measured at baseline, on intensive care unit (ICU) arrival, and on the first postoperative day (POD 1). Both ketamine doses decreased the serum IL-6 response at ICU arrival and POD 1 compared with placebo (p < 0.05). CRP was lower in the 0.5-mg/kg group than placebo on POD 1 (p = 0.003). IL-10 was lower in the ketamine groups (p = 0.01) at POD 1 compared with placebo; IL-8 levels were not affected by ketamine. Mean arterial pressure and systemic vascular resistance were higher at the end of surgery, arrival in the ICU, and POD 1 in the ketamine groups (p < 0.05).

Conclusion: Low-dose ketamine (0.5 mg/kg) attenuates increases in CRP, IL-6, and IL-10 while decreasing vasodilatation after CPB.

Publication types

  • Randomized Controlled Trial
  • Retracted Publication

MeSH terms

  • Aged
  • Biomarkers / blood
  • C-Reactive Protein / metabolism
  • Cardiac Surgical Procedures / methods*
  • Cardiopulmonary Bypass
  • Dose-Response Relationship, Drug
  • Double-Blind Method
  • Excitatory Amino Acid Antagonists / administration & dosage
  • Excitatory Amino Acid Antagonists / therapeutic use*
  • Female
  • Follow-Up Studies
  • Humans
  • Inflammation / blood
  • Inflammation / prevention & control*
  • Interleukin-10 / blood
  • Interleukin-6 / blood
  • Interleukin-8 / blood
  • Ketamine / administration & dosage
  • Ketamine / therapeutic use*
  • Male
  • Postoperative Complications
  • Prognosis
  • Prospective Studies
  • Vasodilation / drug effects

Substances

  • Biomarkers
  • Excitatory Amino Acid Antagonists
  • Interleukin-6
  • Interleukin-8
  • Interleukin-10
  • Ketamine
  • C-Reactive Protein